Neuraminidase (Influenza A virus subtype H5N1) (NA)

Neuraminidase (NA) is a critical surface glycoprotein and essential enzyme of the influenza A virus, including the highly pathogenic H5N1 subtype [4, 10]. It functions as a homotetrameric sialidase that cleaves terminal sialic acid residues from host cell receptors and viral glycoproteins, a process vital for the release of progeny virions from infected cells and the prevention of viral aggregation [7, 13]. Beyond its role in viral egress, NA facilitates the movement of the virus through the respiratory mucus by degrading sialic acid-containing decoy receptors [4, 10]. As a primary therapeutic target, NA is inhibited by small molecules such as oseltamivir, zanamivir, and peramivir, which bind to the enzyme's active site to block viral dissemination [1, 14]. However, the clinical management of H5N1 is challenged by the potential for rapid development of drug-resistant mutations, such as the H274Y substitution, and the high virulence of the virus which often requires early intervention for efficacy [1, 8, 11]. NA is also a major antigenic determinant, and antibodies targeting its conserved epitopes are being investigated for the development of universal influenza vaccines [2, 13]. Furthermore, the balance between NA activity and hemagglutinin binding is a key factor in the adaptation of avian H5N1 viruses to human hosts [5, 15].

Other names

SialidaseN1 neuraminidaseExo-alpha-sialidaseAcetylneuraminyl hydrolaseNeuraminidase antigen

Neuraminidase inhibitors mimic the transition state of sialic acid cleavage, binding with high affinity to the active site of the viral neuraminidase enzyme [7, 14]. This competitive inhibition prevents the enzyme from cleaving sialic acid residues on host cell receptors, which traps newly formed virions on the surface of the infected cell and prevents their release and subsequent infection of other cells [1, 10].